Importance of tumour infiltrating lymphocytes in breast cancer
Not Applicable
- Conditions
- Health Condition 1: C508- Malignant neoplasm of overlappingsites of breast
- Registration Number
- CTRI/2019/03/017932
- Lead Sponsor
- RAJINDER PARSHAD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Newly Diagnosed breast cancer patients enrolled in surgery 3 breast cancer clinic (BCC) will be included in the prospective group.
2) Diagnosed cases of carcinoma breast enrolled in surgery 3 BCC from January 2014 till start of study whose blocks and slides can be retrieved and follow up data available will be included in retrospective group.
3) Consenting to participate
Exclusion Criteria
1) Blocks not available for review in retrospective patients
2) Patients with incomplete data
3) Patients not giving participation consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the expression of Tumour infiltrating lymphocytes and their correlation with standard prognostic factorsTimepoint: 3 monthly for the first two years after surgery followed by 6 monthly till the end of 5 years and then yearly after that .
- Secondary Outcome Measures
Name Time Method To study the correlation between tumour infiltrating lymphocytes and 2 year disease free survivalTimepoint: 2014 - 2020;To study the correlation between tumour infiltrating lymphocytes expression and response to NACT <br/ ><br> <br/ ><br>Timepoint: ETHICS APPROVAL TILL 2020